(19) World Intellectual Property Organization

International Bureau



(43) International Publication Date 21 July 2005 (21.07.2005)

PCT

(10) International Publication Number WO 2005/065693 A2

(51) International Patent Classification7:

A61K 31/70

(21) International Application Number:

PCT/US2004/041815

(22) International Filing Date:

14 December 2004 (14.12.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/533,330

30 December 2003 (30.12.2003)

- (71) Applicant (for all designated States except US): AVEN-TIS PHARMACEUTICALS INC. [US/US]; 300 Somerset Corporate Boulevard, Bridgewater, New Jersey 08807-2854 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): SALTZMAN, Alan G. [US/US]; 183 Buttercup Blvd., Warrington, Pennsylvania 18976 (US). TANG, Zhihua [US/US]; 1748 Foxwood Drive, Jamison, Pennsylvania 18929 (US). PALEJWALA,


Vaseem [US/US]; 2029 Church Street, Scotch Plains, New Jersey 07076 (US). CAVALLO, Jean [US/US]; 13 Fieldstone Drive, Clinton, New Jersey 08809 (US).

- (74) Agents: KRUPEN, Karen, I. et al.; Aventis Pharmaceuticals Inc., Route 202-206||P. O. Box 6800, Bridgewater, NJ 08807-0800 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,

[Continued on next page]

(54) Title: USE OF CATHEPSIN Z INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND OTHER AU-TOIMMUNE DISEASES

Model of Cathepsin Z's role in Antigen Processing



(57) Abstract: Methods for identifying compounds for treating autoimmune diseases including rheumatoid arthritis. Compounds for treating autoimmune diseases including rheumatoid arthritis. Methods of treatment for autoimmune diseases including rheumatoid arthritis. These methods and compounds are directed to inhibiting the activity of Cathespin Z.

WO 2005/065693 A2



SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.